Daniel S. Lorrain, Chief Scientific Officer: Contineum Therapeutics CTNM Planned sale · Filed 09/01

Trade details

Type: Planned sale notice
Stock: Contineum Therapeutics CTNM
Person: Daniel S. LorrainChief Scientific Officer
Planned sale date: 26/09/01
Filed: 26/09/01

More to sell after $765K in 3 months

Contineum Therapeutics trades, last 26 weeks

What else happened in Contineum Therapeutics around then

Filed or reported within 30 days of the trade day · 08/02~10/01

Daniel S. Lorrain's recent trades

Daniel S. LorrainChief Scientific Officer
Planned sale10b5-1 planContineum Therapeutics
Planned sale10b5-1 plan
Contineum Therapeutics
CTNM
$147.5K
9,520 sh
$147.5K
Filed 08/03
Traded 08/03
Daniel S. LorrainChief Scientific Officer
Planned sale10b5-1 planContineum Therapeutics
Planned sale10b5-1 plan
Contineum Therapeutics
CTNM
$156K
9,520 sh
$156K
Filed 07/01
Traded 07/01
Daniel S. LorrainChief Scientific Officer
Planned sale10b5-1 planContineum Therapeutics
Planned sale10b5-1 plan
Contineum Therapeutics
CTNM
$432.4K
28,826 sh
$432.4K
Filed 06/30
Traded 06/30
Daniel S. LorrainChief Scientific Officer
Sell10b5-1 planContineum Therapeutics
Sell10b5-1 plan
Contineum Therapeutics
CTNM
$54.9K
4,170 sh
$54.9K
Filed 06/01
Traded 06/01
Daniel S. LorrainChief Scientific Officer
Planned sale10b5-1 planContineum Therapeutics
Planned sale10b5-1 plan
Contineum Therapeutics
CTNM
$56.3K
4,170 sh
$56.3K
Filed 06/01
Traded 06/01

Daniel S. Lorrain, Chief Officer — plans to sell 9,520 sh of Contineum Therapeutics CTNM · $154.6K · around 09/01 · 10b5-1 plan | Whalegun